Red Biotechnology Market Size, Share & Trends Analysis Report By Product, By End-user (Academic Research Institutes, CMOs & CROs, Pharmaceutical & Biotechnology Companies, Others), By Region, And Segment Forecasts, 2023 - 2030

Report Overview

The global red biotechnology market was valued at USD 515.58 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 10.6% from 2023 to 2030. The increasing demand for personalized medicine, high investment in R&D of biotechnology products, and the rising advances in genetic research. Red biotechnology deals with biotechnological applications such as stem cells, gene therapy, genetic engineering, and the development of new drugs and vaccines. Red biotechnology is a process that uses organisms to improve health care and aid the body in disease-fighting. It is a subset of modern technology used in the field of medicine. Red biotechnology is applicable not only to the pharmaceutical industry but also to the medical sector, as it aids in the alleviation of human suffering and improves the quality of life. The rising usage of genetic engineering to produce biological medicine is one of the major trends. This includes using recombinant DNA technology to create genetically modified organisms capable of producing large amounts of a specific protein, such as a therapeutic antibody.

The market is expected to witness lucrative growth during the forecast period. The market has made significant advances in disease control, from antibiotics for treating acute microbial infections to chronic conditions such as anti-HIV/AIDS. One of which being azidothymidine which has helped managing AIDS.

Many pharmaceutical companies are developing and manufacturing pipeline products for diabetes and neurological disorders such as Alzheimer's and Parkinson's disease. According to the clinicaltrials.gov, there were 126 agents in clinical trials for the treatment of Alzheimer's disease as of January 2021, with 28 treatments in phase III trials. Fermentation technology is being widely used in the life sciences and healthcare sectors, which is positively impacting market growth.

The market is still a growing field with enormous potential for driving medical advancements and transforming the identification of diseases caused by genetic factors. Novel tests can detect changes in the DNA sequence of genes linked to disease risk. Early detection is frequently the crucial factor in avoiding disease or slowing disease progression through early treatment.

The pandemic of COVID-19 has had a significant impact on the red biotechnology market. The biotechnology industry has always relied heavily on innovation. Even in the presence of the COVID-19 pandemic, significant progress is being made in the discovery and development of novel drugs. Despite the numerous challenges posed by the pandemic, the key growth drivers for red biotechnology have remained intact, and the industry will continue to generate innovative new drugs in both the short and long term.

Furthermore, as a result of the COVID-19 pandemic, drug developers are facing some new operational challenges, and anticipate some influence on clinical trial timelines as well as the number of new drug approvals in the future. The market players that are actively running clinical trials for investigational drugs are experiencing a slowdown in patient enrollment and have been forced to temporarily close trial sites entirely, as hospitals prioritize COVID-19 patients' treatment. The pipeline of COVID-19 drugs and vaccines is growing at an unprecedented rate and will be effective in treating and preventing infections.

Products Insights

Monoclonal antibodies held the major share of the red biotechnology market with 43.1% in 2022. The rising prevalence of chronic diseases such as cardiovascular disease, cancer, etc. is increasing the demand for biologics, which is expected to serve as a key factor driving the segment's growth. Furthermore, the COVID-19 pandemic has fueled the development of several mAbs directed against the SARS-CoV-2 virus, which has increased market expansion prospects. The mAbs are a promising alternative for COVID-19 mitigation due to their safety and effectiveness, several of these antibodies have received emergency use authorizations from the U.S. FDA.

Gene therapy products are likely to witness the fastest growth in the market. It is expected to expand at a CAGR of 24.3% between 2023 and 2030. The growth can be attributed to factors such as the expansion of gene delivery technologies and advanced therapies, as well as the development of progressive competition among major market players focused on the commercialization of their therapies. According to the American Society of Gene & Cell Therapy (ASGCT), approximately 1,986 gene therapy products are in development, including genetically modified cell therapies and CAR T-cell therapies.

End-user Insights

Pharmaceutical & biotechnology companies are expected to account for the largest market share in 2022. The segment contributed 45.6% of revenues in 2022. Pharmaceutical and biotechnology companies are dealing with a variety of challenging trends. The global demand for COVID-19 vaccines and therapeutics is increasing rapidly, placing an added burden on the industry. The company's ability to find an innovative way to provide COVID-19 vaccines while still meeting overall demand is remarkable, but rising global demand remains a significant long-term challenge for the industry. These businesses are experiencing a wave of innovation, from new treatment modalities to advanced analytics, smart machines, and digital connectivity.

CMOs & CROs is the fastest-growing sub-segment. It is expected to expand at a CAGR of 12.8% between 2023 and 2030. The increasing investment in the biotechnology industry by prominent players to enhance their efficiency and productivity has driven biopharmaceutical manufacturers to increase their focus on outsourcing services. Mergers and acquisitions allow CMOs to offer inclusive bioprocessing services, making CMOs/CROs a feasible option for rapid product launches. The market for CMOs and CROs is still in its early stages, but the introduction of novel therapeutics, new bioprocessing tools, and product priority shifts in the bio/pharmaceutical industry has increased the pressure on contract bio manufacturers.

Regional Insights

North America accounted for the largest share of 38.07% in the market in 2022. The large share is mainly attributed to an increase in R&D activities and technological advancements in the field of biotechnology. The U.S. is among the key markets in the biotechnology industry. Major factors such as developed infrastructure, and the rise in the incidence of various diseases are driving the market growth in the region. For instance, In June 2022, a gene therapy developed by Bluebird Bio received support from advisors and is currently being evaluated by the U.S. FDA for the treatment of cerebral adrenoleukodystrophy in patients under the age of 18.

Asia Pacific will likely emerge as the fastest region during the study period. The emerging economies of Asia Pacific countries such as India, and China are majorly contributing to the growth of this region. These countries are involved into private-public collaborations, and government initiatives that are propelling the growth of Asian market.

Key Companies & Market Share Insights

The increasing demand for red biotechnology for various applications has created numerous market opportunities for the market players to capitalize on. Companies are involved in strategic initiatives such as new product launches, collaborations, and acquisitions to propel their market share. Some of the key players in the global red biotechnology market include:

• Merck KGaA

• F. Hoffmann-La Roche AG

• Pfizer Inc.

• Regeneron Pharmaceuticals, Inc.

• AstraZeneca Plc

• Takeda Pharmaceutical Company Limited

• Gilead Sciences

• Biogen Inc.

• Amgen Inc.

• Celgene Corporation

Red Biotechnology Market Report Scope

Global Red Biotechnology Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented red biotechnology market report based on product, end-user, and region.

• Product Outlook (Revenue, USD Billion, 2018 - 2030)

  • Monoclonal Antibodies

  • Polyclonal Antibodies

  • Recombinant Proteins

  • Vaccines

  • Cell-Based Immunotherapy Products

  • Gene Therapy Products

  • Cell Therapy Products

  • Tissue-Engineered Products

  • Stem Cells

  • Cell Culture

  • Viral Vector

  • Enzymes

  • Kits and Reagents

  • Animal models

  • Molecular diagnostics

  • Others

• End-User Outlook (Revenue, USD Billion, 2018 - 2030)

  • Academic Research Institutes

  • CMOs & CROs

  • Pharmaceutical & Biotechnology Companies

  • Others

• Regional Outlook (Revenue, USD Billion, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait